Mainz Biomed (NASDAQ:MYNZ – Get Rating) and Otonomy (NASDAQ:OTIC – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, dividends, valuation and earnings.
Analyst Recommendations
This is a summary of recent ratings for Mainz Biomed and Otonomy, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mainz Biomed | 0 | 0 | 3 | 0 | 3.00 |
| Otonomy | 0 | 2 | 0 | 0 | 2.00 |
Mainz Biomed presently has a consensus target price of $17.00, suggesting a potential upside of 338.14%. Otonomy has a consensus target price of $0.50, suggesting a potential upside of 5,782.35%. Given Otonomy’s higher possible upside, analysts plainly believe Otonomy is more favorable than Mainz Biomed.
Volatility and Risk
Insider & Institutional Ownership
0.1% of Mainz Biomed shares are held by institutional investors. Comparatively, 41.2% of Otonomy shares are held by institutional investors. 18.2% of Mainz Biomed shares are held by company insiders. Comparatively, 1.1% of Otonomy shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Mainz Biomed and Otonomy’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Mainz Biomed | N/A | N/A | N/A |
| Otonomy | N/A | -137.86% | -68.50% |
Earnings and Valuation
This table compares Mainz Biomed and Otonomy’s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Mainz Biomed | $530,000.00 | 87.92 | -$26.39 million | N/A | N/A |
| Otonomy | $130,000.00 | 4.48 | -$51.18 million | ($0.77) | -0.01 |
Mainz Biomed has higher revenue and earnings than Otonomy.
Summary
Mainz Biomed beats Otonomy on 8 of the 11 factors compared between the two stocks.
About Mainz Biomed
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
About Otonomy
Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm’s product pipeline includes OTIVIDEX (dexamethasone) Meniere’s disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.
Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
